r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

JA

Jeffrey W. Albers

Insider · Director · SYRE

Jeffrey W. Albers files insider transactions with the SEC as a director of Spyre Therapeutics. We hold 1 disclosed purchase or sale filed since 4 November 2015, 1 of them in the last 90 days.

  • Files for 5 companiesSYRE, KYMR, BPMC, AGLE and 1 more
  • Disclosed buys and sells1 in all, 1 in the last 90 days
  • Last disclosure10 August 2026

Positions held

5 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 22 November 2023 — 7 August 2026Director · Spyre Therapeutics 13 Form 4 lines · source: SEC Form 4
  • Filed 20 August 2020 — 24 June 2026Director · Kymera Therapeutics 29 Form 4 lines · source: SEC Form 4
  • Filed 2 November 2015 — 17 July 2025CEO and President · Blueprint Medicines 303 Form 4 lines · source: SEC Form 4
  • Filed 22 November 2023 — 22 November 2023Director · Spyre Therapeutics 1 Form 4 line · source: SEC Form 4
  • Filed 25 June 2018 — 28 June 2022Director · Magenta Therapeutics 6 Form 4 lines · source: SEC Form 4

Every transaction

352 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
352 of 352 shown
7 Aug 202610 Aug 2026SEC Form 43 dexercised options overnot a tradeSpyre Therapeutics5,000 sharesdown −17.1%down −17.5%
7 Aug 202610 Aug 2026SEC Form 43 dsold on the open marketSpyre Therapeutics5,000 sharesdown −17.1%down −17.5%
7 Aug 202610 Aug 2026SEC Form 43 dsold on the open marketSpyre Therapeutics8,000 sharesdown −17.1%down −17.5%
7 Aug 202610 Aug 2026SEC Form 43 dsold on the open marketSpyre Therapeutics10,000 sharesdown −17.1%down −17.5%
7 Aug 202610 Aug 2026SEC Form 43 dexercised options overnot a tradeSpyre Therapeuticsderivative5,000 sharesdown −17.1%down −17.5%
24 Jun 202625 Jun 2026SEC Form 41 dwas grantednot a tradeKymera Therapeuticsderivative6,068 sharesup +15.6%down −0.9%
27 May 202629 May 2026SEC Form 42 dwas grantednot a tradeSpyre Therapeuticsderivative8,026 sharesup +19.9%up +18.3%
8 Dec 20258 Dec 2025SEC Form 40 dexercised options overnot a tradeKymera Therapeuticsderivative5,000 sharesup +22.4%up +22.4%
8 Dec 20258 Dec 2025SEC Form 40 dexercised options overnot a tradeKymera Therapeutics5,000 sharesup +22.4%up +22.4%
8 Dec 20258 Dec 2025SEC Form 40 dsold on the open marketKymera Therapeutics2,748 sharesup +22.4%up +22.4%
8 Dec 20258 Dec 2025SEC Form 40 dsold on the open marketKymera Therapeutics2,252 sharesup +22.4%up +22.4%
13 Oct 202514 Oct 2025SEC Form 41 dexercised options overnot a tradeKymera Therapeuticsderivative5,000 sharesup +92.7%up +98.1%
13 Oct 202514 Oct 2025SEC Form 41 dexercised options overnot a tradeKymera Therapeutics5,000 sharesup +92.7%up +98.1%
13 Oct 202514 Oct 2025SEC Form 41 dsold on the open marketKymera Therapeutics5,000 sharesup +92.7%up +98.1%
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative92,500 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative170,000 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative110,500 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative90,000 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative80,000 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative5,300 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicinesderivative4,570 shares——
17 Jul 202521 Jul 2025SEC Form 44 dreturned to the issuernot a tradeBPMCBlueprint Medicines5,777 shares——
17 Jul 202521 Jul 2025SEC Form 44 ddisposed of in a tender offernot a tradeBPMCBlueprint Medicines144,755 shares——
25 Jun 202526 Jun 2025SEC Form 41 dwas grantednot a tradeKymera Therapeuticsderivative16,000 sharesup +148.4%up +152.5%
18 Jun 202524 Jun 2025SEC Form 46 dwas grantednot a tradeBPMCBlueprint Medicines3,902 shares——
3 Jun 20253 Jun 2025SEC Form 40 dexercised options overnot a tradeKymera Therapeuticsderivative6,349 sharesup +164.9%up +164.9%
3 Jun 20253 Jun 2025SEC Form 40 dexercised options overnot a tradeKymera Therapeutics6,349 sharesup +164.9%up +164.9%
3 Jun 20253 Jun 2025SEC Form 40 dsold on the open marketKymera Therapeutics6,349 sharesup +164.9%up +164.9%
29 May 20252 Jun 2025SEC Form 44 dwas grantednot a tradeSpyre Therapeuticsderivative25,000 sharesup +459.0%up +464.5%
27 May 202529 May 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
27 May 202529 May 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
27 May 202529 May 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,350 shares——
27 May 202529 May 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines650 shares——
12 Mar 202514 Mar 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,500 shares——
12 Mar 202514 Mar 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines7,500 shares——
12 Mar 202514 Mar 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,700 shares——
12 Mar 202514 Mar 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,800 shares——
5 Mar 202517 Mar 2025SEC Form 412 dsold on the open marketBPMCBlueprint Medicines5,766 shares——
21 Jan 202523 Jan 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
21 Jan 202523 Jan 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
21 Jan 202523 Jan 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,561 shares——
21 Jan 202523 Jan 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,400 shares——
21 Jan 202523 Jan 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines200 shares——
13 Jan 202515 Jan 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
13 Jan 202515 Jan 2025SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
13 Jan 202515 Jan 2025SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
19 Dec 202420 Dec 2024SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
19 Dec 202420 Dec 2024SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicines15,000 shares——
19 Dec 202420 Dec 2024SEC Form 41 dsold on the open marketBPMCBlueprint Medicines3,920 shares——
19 Dec 202420 Dec 2024SEC Form 41 dsold on the open marketBPMCBlueprint Medicines5,180 shares——
19 Dec 202420 Dec 2024SEC Form 41 dsold on the open marketBPMCBlueprint Medicines3,800 shares——
19 Dec 202420 Dec 2024SEC Form 41 dsold on the open marketBPMCBlueprint Medicines2,100 shares——
7 Nov 202412 Nov 2024SEC Form 45 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
7 Nov 202412 Nov 2024SEC Form 45 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
7 Nov 202412 Nov 2024SEC Form 45 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
6 Nov 20248 Nov 2024SEC Form 42 dsold on the open marketSpyre Therapeutics6,700 sharesup +131.9%up +119.7%
25 Oct 202428 Oct 2024SEC Form 43 dsold on the open marketSpyre Therapeutics300 sharesup +149.7%up +152.7%
9 Sep 202411 Sep 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
9 Sep 202411 Sep 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
9 Sep 202411 Sep 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines11,968 shares——
9 Sep 202411 Sep 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,734 shares——
26 Aug 202426 Aug 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeuticsderivative5,000 sharesup +132.0%up +132.0%
26 Aug 202426 Aug 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeutics5,000 sharesup +132.0%up +132.0%
26 Aug 202426 Aug 2024SEC Form 40 dsold on the open marketKymera Therapeutics5,000 sharesup +132.0%up +132.0%
18 Jun 202420 Jun 2024SEC Form 42 dwas grantednot a tradeKymera Therapeuticsderivative16,000 sharesup +270.0%up +269.1%
12 Jun 202414 Jun 2024SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative4,570 shares——
12 Jun 202414 Jun 2024SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicines2,242 shares——
14 May 202416 May 2024SEC Form 42 dwas grantednot a tradeSpyre Therapeuticsderivative11,323 sharesup +121.3%up +130.0%
20 Mar 202422 Mar 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative15,073 shares——
20 Mar 202422 Mar 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
20 Mar 202422 Mar 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines15,073 shares——
20 Mar 202422 Mar 2024SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
20 Mar 202422 Mar 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,730 shares——
20 Mar 202422 Mar 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,251 shares——
20 Mar 202422 Mar 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines8,440 shares——
20 Mar 202422 Mar 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,285 shares——
20 Mar 202422 Mar 2024SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,367 shares——
7 Mar 202426 Mar 2024SEC Form 419 dsold on the open marketBPMCBlueprint Medicines11,033 shares——
21 Feb 202421 Feb 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeuticsderivative4,385 sharesup +198.5%up +198.5%
21 Feb 202421 Feb 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeutics4,385 sharesup +198.5%up +198.5%
21 Feb 202421 Feb 2024SEC Form 40 dsold on the open marketKymera Therapeutics4,385 sharesup +198.5%up +198.5%
20 Feb 202421 Feb 2024SEC Form 41 dexercised options overnot a tradeKymera Therapeuticsderivative615 sharesup +203.5%up +198.5%
20 Feb 202421 Feb 2024SEC Form 41 dexercised options overnot a tradeKymera Therapeutics615 sharesup +203.5%up +198.5%
20 Feb 202421 Feb 2024SEC Form 41 dsold on the open marketKymera Therapeutics615 sharesup +203.5%up +198.5%
25 Jan 202429 Jan 2024SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
25 Jan 202429 Jan 2024SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
25 Jan 202429 Jan 2024SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines15,000 shares——
25 Jan 202429 Jan 2024SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
25 Jan 202429 Jan 2024SEC Form 44 dsold on the open marketBPMCBlueprint Medicines6,086 shares——
25 Jan 202429 Jan 2024SEC Form 44 dsold on the open marketBPMCBlueprint Medicines10,890 shares——
25 Jan 202429 Jan 2024SEC Form 44 dsold on the open marketBPMCBlueprint Medicines7,924 shares——
25 Jan 202429 Jan 2024SEC Form 44 dsold on the open marketBPMCBlueprint Medicines100 shares——
23 Jan 202423 Jan 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeuticsderivative10,000 sharesup +269.1%up +269.1%
23 Jan 202423 Jan 2024SEC Form 40 dexercised options overnot a tradeKymera Therapeutics10,000 sharesup +269.1%up +269.1%
23 Jan 202423 Jan 2024SEC Form 40 dsold on the open marketKymera Therapeutics10,000 sharesup +269.1%up +269.1%
11 Dec 202313 Dec 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
11 Dec 202313 Dec 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
11 Dec 202313 Dec 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
30 Nov 20234 Dec 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
30 Nov 20234 Dec 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
30 Nov 20234 Dec 2023SEC Form 44 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
24 Nov 20238 Dec 2023SEC Form 414 dconvertednot a tradeSpyre Therapeuticsderivative859 sharesup +687.4%up +343.3%
24 Nov 20238 Dec 2023SEC Form 414 dconvertednot a tradeSpyre Therapeutics34,360 sharesup +687.4%up +343.3%
24 Nov 202328 Nov 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
24 Nov 202328 Nov 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines15,000 shares——
24 Nov 202328 Nov 2023SEC Form 44 dsold on the open marketBPMCBlueprint Medicines7,964 shares——
24 Nov 202328 Nov 2023SEC Form 44 dsold on the open marketBPMCBlueprint Medicines7,036 shares——
22 Nov 20238 Dec 2023SEC Form 416 dwas grantednot a tradeSpyre Therapeuticsderivative50,000 sharesup +736.7%up +343.3%
22 Nov 202327 Nov 2023SEC Form 45 dwas grantednot a tradeSpyre Therapeuticsderivative50,000 sharesup +736.7%up +623.8%
3 Nov 20233 Nov 2023SEC Form 40 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative1,485 shares——
3 Nov 20233 Nov 2023SEC Form 40 dexercised options overnot a tradeBPMCBlueprint Medicines1,485 shares——
3 Nov 20233 Nov 2023SEC Form 40 dsold on the open marketBPMCBlueprint Medicines1,485 shares——
2 Nov 20233 Nov 2023SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative4,634 shares——
2 Nov 20233 Nov 2023SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicines4,634 shares——
2 Nov 20233 Nov 2023SEC Form 41 dsold on the open marketBPMCBlueprint Medicines4,575 shares——
2 Nov 20233 Nov 2023SEC Form 41 dsold on the open marketBPMCBlueprint Medicines59 shares——
1 Nov 20233 Nov 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative3,881 shares——
1 Nov 20233 Nov 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines3,881 shares——
1 Nov 20233 Nov 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines3,881 shares——
28 Sep 202329 Sep 2023SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative6,898 shares——
28 Sep 202329 Sep 2023SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicines6,898 shares——
28 Sep 202329 Sep 2023SEC Form 41 dsold on the open marketBPMCBlueprint Medicines6,898 shares——
27 Sep 202329 Sep 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative18,102 shares——
27 Sep 202329 Sep 2023SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines18,102 shares——
27 Sep 202329 Sep 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,600 shares——
27 Sep 202329 Sep 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines12,102 shares——
27 Sep 202329 Sep 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines400 shares——
25 Aug 202328 Aug 2023SEC Form 43 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
25 Aug 202328 Aug 2023SEC Form 43 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
25 Aug 202328 Aug 2023SEC Form 43 dsold on the open marketBPMCBlueprint Medicines10,000 shares——
24 Aug 202328 Aug 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
24 Aug 202328 Aug 2023SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines15,000 shares——
24 Aug 202328 Aug 2023SEC Form 44 dsold on the open marketBPMCBlueprint Medicines15,000 shares——
21 Jun 202323 Jun 2023SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative5,300 shares——
21 Jun 202323 Jun 2023SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicines2,600 shares——
15 Jun 202320 Jun 2023SEC Form 45 dwas grantednot a tradeKymera Therapeuticsderivative12,000 sharesup +317.2%up +358.2%
6 Mar 20238 Mar 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines9,474 shares——
6 Mar 20238 Mar 2023SEC Form 42 dsold on the open marketBPMCBlueprint Medicines319 shares——
5 Dec 20227 Dec 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
5 Dec 20227 Dec 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
5 Dec 20227 Dec 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
5 Dec 20227 Dec 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
5 Dec 20227 Dec 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines20,000 shares——
22 Aug 202223 Aug 2022SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative8,410 shares——
22 Aug 202223 Aug 2022SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicines8,410 shares——
22 Aug 202223 Aug 2022SEC Form 41 dsold on the open marketBPMCBlueprint Medicines7,748 shares——
22 Aug 202223 Aug 2022SEC Form 41 dsold on the open marketBPMCBlueprint Medicines662 shares——
19 Aug 202223 Aug 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative1,590 shares——
19 Aug 202223 Aug 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines1,590 shares——
19 Aug 202223 Aug 2022SEC Form 44 dsold on the open marketBPMCBlueprint Medicines1,590 shares——
16 Aug 202218 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
16 Aug 202218 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
16 Aug 202218 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
16 Aug 202218 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
16 Aug 202218 Aug 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,230 shares——
16 Aug 202218 Aug 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines12,477 shares——
16 Aug 202218 Aug 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines293 shares——
8 Aug 202210 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,170 shares——
8 Aug 202210 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative2,830 shares——
8 Aug 202210 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines7,170 shares——
8 Aug 202210 Aug 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines2,830 shares——
8 Aug 202210 Aug 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines10,000 shares——
28 Jun 202230 Jun 2022SEC Form 42 dwas grantednot a tradeMagenta Therapeuticsderivative20,000 sharesup +452.9%up +457.5%
15 Jun 202216 Jun 2022SEC Form 41 dwas grantednot a tradeKymera Therapeuticsderivative12,000 sharesup +714.0%up +710.0%
16 May 202218 May 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
16 May 202218 May 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
16 May 202218 May 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
16 May 202218 May 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
16 May 202218 May 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,900 shares——
16 May 202218 May 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,342 shares——
16 May 202218 May 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines12,758 shares——
6 Apr 20228 Apr 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
6 Apr 20228 Apr 2022SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
6 Apr 20228 Apr 2022SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
7 Mar 20228 Mar 2022SEC Form 41 dsold on the open marketBPMCBlueprint Medicines4,843 shares——
4 Mar 20228 Mar 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,500 shares——
4 Mar 20228 Mar 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative12,500 shares——
4 Mar 20228 Mar 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines7,500 shares——
4 Mar 20228 Mar 2022SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines12,500 shares——
4 Mar 20228 Mar 2022SEC Form 44 dsold on the open marketBPMCBlueprint Medicines10,055 shares——
4 Mar 20228 Mar 2022SEC Form 44 dsold on the open marketBPMCBlueprint Medicines4,445 shares——
4 Mar 20228 Mar 2022SEC Form 44 dsold on the open marketBPMCBlueprint Medicines4,100 shares——
4 Mar 20228 Mar 2022SEC Form 44 dsold on the open marketBPMCBlueprint Medicines1,400 shares——
3 Mar 20228 Mar 2022SEC Form 45 dsold on the open marketBPMCBlueprint Medicines7,862 shares——
1 Mar 20223 Mar 2022SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative15,000 shares——
1 Mar 20223 Mar 2022SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicines7,500 shares——
15 Nov 202117 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,500 shares——
15 Nov 202117 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative22,500 shares——
15 Nov 202117 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines7,500 shares——
15 Nov 202117 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines22,500 shares——
15 Nov 202117 Nov 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines21,906 shares——
15 Nov 202117 Nov 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,894 shares——
15 Nov 202117 Nov 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines100 shares——
15 Nov 202117 Nov 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines100 shares——
1 Nov 20213 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
1 Nov 20213 Nov 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
1 Nov 20213 Nov 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
26 Aug 202130 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative16,000 shares——
26 Aug 202130 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines16,000 shares——
19 Aug 202123 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative17,500 shares——
19 Aug 202123 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,500 shares——
19 Aug 202123 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines7,500 shares——
19 Aug 202123 Aug 2021SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines17,500 shares——
19 Aug 202123 Aug 2021SEC Form 44 dsold on the open marketBPMCBlueprint Medicines14,815 shares——
19 Aug 202123 Aug 2021SEC Form 44 dsold on the open marketBPMCBlueprint Medicines10,185 shares——
16 Jun 202117 Jun 2021SEC Form 41 dwas grantednot a tradeKymera Therapeuticsderivative20,063 sharesup +135.1%up +142.2%
1 Jun 20213 Jun 2021SEC Form 42 dwas grantednot a tradeMagenta Therapeuticsderivative18,188 sharesdown −48.2%down −47.3%
12 May 202114 May 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative17,500 shares——
12 May 202114 May 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative7,500 shares——
12 May 202114 May 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines7,500 shares——
12 May 202114 May 2021SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines17,500 shares——
12 May 202114 May 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,664 shares——
12 May 202114 May 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines16,383 shares——
12 May 202114 May 2021SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,953 shares——
4 Mar 20215 Mar 2021SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative10,000 shares——
4 Mar 20215 Mar 2021SEC Form 41 dexercised options overnot a tradeBPMCBlueprint Medicines10,000 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines1,100 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines5,296 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines3,000 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines404 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines100 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines100 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines569 shares——
4 Mar 20215 Mar 2021SEC Form 41 dsold on the open marketBPMCBlueprint Medicines8,417 shares——
1 Mar 20213 Mar 2021SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative80,000 shares——
1 Mar 20213 Mar 2021SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicines40,000 shares——
14 Dec 202016 Dec 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
14 Dec 202016 Dec 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
14 Dec 202016 Dec 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
16 Nov 202018 Nov 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
16 Nov 202018 Nov 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
16 Nov 202018 Nov 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,127 shares——
16 Nov 202018 Nov 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,869 shares——
16 Nov 202018 Nov 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,483 shares——
16 Nov 202018 Nov 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,521 shares——
7 Oct 20209 Oct 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
7 Oct 20209 Oct 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
7 Oct 20209 Oct 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
20 Aug 202021 Aug 2020SEC Form 41 dwas grantednot a tradeKymera Therapeuticsderivative40,127 shares—up +247.1%
19 Aug 202021 Aug 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
19 Aug 202021 Aug 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
19 Aug 202021 Aug 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines11,403 shares——
19 Aug 202021 Aug 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines8,597 shares——
5 Jun 20209 Jun 2020SEC Form 44 dwas grantednot a tradeMagenta Therapeuticsderivative18,188 sharesdown −33.0%down −36.6%
12 May 202014 May 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
12 May 202014 May 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
12 May 202014 May 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,150 shares——
12 May 202014 May 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,282 shares——
12 May 202014 May 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines9,568 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative80 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative19,920 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines80 shares——
23 Mar 202025 Mar 2020SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines19,920 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines484 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines3,293 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,936 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,100 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines8,850 shares——
23 Mar 202025 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines3,337 shares——
9 Mar 202011 Mar 2020SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,277 shares——
1 Mar 20203 Mar 2020SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative90,000 shares——
1 Mar 20203 Mar 2020SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicines45,000 shares——
18 Nov 201920 Nov 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative18,000 shares——
18 Nov 201920 Nov 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative2,000 shares——
18 Nov 201920 Nov 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines18,000 shares——
18 Nov 201920 Nov 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines2,000 shares——
18 Nov 201920 Nov 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines600 shares——
18 Nov 201920 Nov 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,656 shares——
8 Nov 201920 Nov 2019SEC Form 412 dsold on the open marketBPMCBlueprint Medicines11,744 shares——
30 Oct 201930 Oct 2019SEC Form 40 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
30 Oct 201930 Oct 2019SEC Form 40 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
19 Aug 201921 Aug 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
19 Aug 201921 Aug 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
19 Aug 201921 Aug 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines100 shares——
19 Aug 201921 Aug 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines800 shares——
19 Aug 201921 Aug 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines300 shares——
19 Aug 201921 Aug 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,634 shares——
19 Aug 201921 Aug 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines12,166 shares——
17 Jun 201919 Jun 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative5,000 shares——
17 Jun 201919 Jun 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines5,000 shares——
17 Jun 201919 Jun 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines5,000 shares——
12 Jun 201914 Jun 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
12 Jun 201914 Jun 2019SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
12 Jun 201914 Jun 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines9,191 shares——
12 Jun 201914 Jun 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,859 shares——
12 Jun 201914 Jun 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines4,050 shares——
12 Jun 201914 Jun 2019SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,900 shares——
7 Jun 201911 Jun 2019SEC Form 44 dwas grantednot a tradeMagenta Therapeuticsderivative18,188 sharesdown −50.1%down −52.8%
15 Mar 201919 Mar 2019SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
15 Mar 201919 Mar 2019SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
15 Mar 201919 Mar 2019SEC Form 44 dsold on the open marketBPMCBlueprint Medicines4,451 shares——
15 Mar 201919 Mar 2019SEC Form 44 dsold on the open marketBPMCBlueprint Medicines9,423 shares——
15 Mar 201919 Mar 2019SEC Form 44 dsold on the open marketBPMCBlueprint Medicines6,126 shares——
1 Mar 20195 Mar 2019SEC Form 44 dwas grantednot a tradeBPMCBlueprint Medicinesderivative110,500 shares——
1 Mar 20195 Mar 2019SEC Form 44 dwas grantednot a tradeBPMCBlueprint Medicinesderivative29,750 shares——
19 Nov 201821 Nov 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines28,961 shares——
19 Nov 201821 Nov 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative28,961 shares——
5 Nov 20187 Nov 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
5 Nov 20187 Nov 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
5 Nov 20187 Nov 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,100 shares——
5 Nov 20187 Nov 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,500 shares——
5 Nov 20187 Nov 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines17,300 shares——
5 Nov 20187 Nov 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines100 shares——
6 Aug 20188 Aug 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
6 Aug 20188 Aug 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines6,179 shares——
6 Aug 20188 Aug 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines12,219 shares——
6 Aug 20188 Aug 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines800 shares——
6 Aug 20188 Aug 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines802 shares——
6 Aug 20188 Aug 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeMagenta Therapeutics4,152 sharesdown −53.1%down −52.4%
25 Jun 201827 Jun 2018SEC Form 42 dconvertednot a tradeMagenta Therapeuticsderivative10,729 sharesdown −53.1%down −52.4%
7 May 20189 May 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
7 May 20189 May 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines11,680 shares——
7 May 20189 May 2018SEC Form 42 dsold on the open marketBPMCBlueprint Medicines8,320 shares——
7 May 20189 May 2018SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
2 Mar 20186 Mar 2018SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicines20,000 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines6,022 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines3,794 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines1,900 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines4,100 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines600 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines2,284 shares——
2 Mar 20186 Mar 2018SEC Form 44 dsold on the open marketBPMCBlueprint Medicines1,300 shares——
2 Mar 20186 Mar 2018SEC Form 44 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative20,000 shares——
16 Feb 201820 Feb 2018SEC Form 44 dwas grantednot a tradeBPMCBlueprint Medicinesderivative170,000 shares——
6 Nov 20178 Nov 2017SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicines24,514 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines400 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,999 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,600 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,432 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines16,469 shares——
6 Nov 20178 Nov 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,100 shares——
6 Nov 20178 Nov 2017SEC Form 42 dexercised options overnot a tradeBPMCBlueprint Medicinesderivative24,514 shares——
8 Aug 20179 Aug 2017SEC Form 41 dsold on the open marketBPMCBlueprint Medicines10,000 shares——
7 Aug 20179 Aug 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines17,214 shares——
7 Aug 20179 Aug 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,786 shares——
28 Jun 201730 Jun 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,566 shares——
28 Jun 201730 Jun 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines10,205 shares——
28 Jun 201730 Jun 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines2,229 shares——
14 Mar 201716 Mar 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines19,020 shares——
14 Mar 201716 Mar 2017SEC Form 42 dsold on the open marketBPMCBlueprint Medicines980 shares——
16 Feb 201721 Feb 2017SEC Form 45 dwas grantednot a tradeBPMCBlueprint Medicinesderivative170,000 shares——
8 Aug 201610 Aug 2016SEC Form 42 dsold on the open marketBPMCBlueprint Medicines15,992 shares——
8 Aug 201610 Aug 2016SEC Form 42 dsold on the open marketBPMCBlueprint Medicines1,008 shares——
3 Jun 20167 Jun 2016SEC Form 44 dsold on the open marketBPMCBlueprint Medicines17,000 shares——
6 Apr 20168 Apr 2016SEC Form 42 dsold on the open marketBPMCBlueprint Medicines17,000 shares——
3 Feb 20165 Feb 2016SEC Form 42 dwas grantednot a tradeBPMCBlueprint Medicinesderivative140,000 shares——
10 Nov 201512 Nov 2015SEC Form 42 dsold on the open marketBPMCBlueprint Medicines7,000 shares——
2 Nov 20154 Nov 2015SEC Form 42 dsold on the open marketBPMCBlueprint Medicines10,000 shares——

Both percentages are the stock’s move, not Jeffrey W. Albers’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 48 of the 352 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.